: Group Art Unit: 1625

Applicant(s): Pedro Harold Han Hermkens

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application N	lo.: 10	/534,945	Examiner: Morris, Patricia L.		
Filed: May 6	, 2005		: Confirmation No. 1701		
		in the Treatment of Androgen- ted Diseases	: Date: December 7, 2009		
			_×.		
	sui	PPLEMENTAL INFORMATION	DISCLOSURE STATEMENT		
Commission P.O. Box 14: Alexandria,	50				
Sir:					
record in the patent applic to have read documents a	isted of above cations, ly acces are not l	n the accompanying Forms PT0 e-identified patent application. 0 copies of these documents ⊠ a			
		ttention is directed to related and the references cited in the	case US application No. 11/587,192 filed case.		
(b)	No fee is believed due because:				
		This Information Disclosure S the filing of the above-identified	tatement is being submitted concurrently with d application; or		
		This Information Disclosure S	Statement is being submitted within three (3)		

Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

 No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of

the undersigned after making reasonable inquiry, no item of

This Information Disclosure Statement is being submitted concurrently with

This Information Disclosure Statement is being submitted prior to the

This Information Disclosure Statement is being submitted before the mailing date of any final action, notice of allowance or an action that

months of the filing date of the above-identified application, or

a Request for Continued Examination (RCE), or

mailing of a first Office Action on the merits.

otherwise closes prosecution; and

(c)

 \boxtimes

2012				
			known to any individu	in this Information Disclosure Statement was ual designated in § 1.56(c) more than three ing of this Information Disclosure Statement;
				hereby authorized to charge the requisite fee Fee Transmittal Sheet.
(d) [formation Disclosure S	Statement is being submitted on or before the
			Statement was first ci office in a counterpa	tion contained in this Information Disclosure ted in a communication from a foreign patent art foreign application not more than three ing of this Information Disclosure Statement;
			Statement was cited office in a counterpart the undersigned after information contained known to any individual.	on contained in this Information Disclosure in a communication from a foreign patient foreign application, and, to the knowledge of er making reasonable inquiry, no item of in this Information Disclosure Statement was ual designated in § 1.56(c) more than three ling of this Information Disclosure Statement;
			The Commissioner is	hereby authorized to charge the requisite fee.
The Cor this Info No. <u>50-</u> 4	rmatic	ioner is on Disc	s hereby authorized to closure Statement, or	charge any fees which may be required for credit any overpayment to Deposit Account
docume	nts ar	e prior	nese documents is not art. The documents ion of the present case	to be presumed as an admission that these are being furnished solely for their possible .
Date: D	ecemi	ber 7, :	2009	Respectfully submitted,
Organon International Inc. Patent Department c/o Schering-Plough Corporation				By Swampley
2000 Galloping Hill Road				Susan Hess
Kenilworth, New Jersey 07033-0530 K-6-1; MS 1990 Tel: (908) 298-2161				Registration No.: 37,350 Attorney For Applicant(s)
Fax: (908				

 \boxtimes